New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis in patients with moderate to severe nonproliferative diabetic retinopathy without diabetic macular edema underscore the need for an evidence-based shift to proactive diabetic retinopathy (DR) treatment (rather than “watch and wait”). Guideline recommendations do not reflect the available treatments, and strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products) continue to evolve and emerge, challenging clinicians to stay current and highlighting the need for individualized treatment and shared decision-making in DR treatment. This activity provides guidance for treatment of DR/diabetic macular edema (DME) with anti-VEGF agents, strategies to reduce anti-VEGF treatment burden (eg, treat-and-extend dosing, high-dose and novel agents, and novel products), and highlights the need for individualized treatment and shared decision-making in DR treatment.

CME/CE Accreditation Information

Diabetic retinopathy and diabetic macular edema affect a majority of patients with diabetes, but there are ways to mitigate its progression. You'll learn practical strategies to help patients save their sight and you'll discuss the integration of novel screening and diagnostic technology into primary care settings.

CME/CE Accreditation Information